These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10800562)

  • 1. [The concept of herd immunity applied to the evaluation of vaccination programs].
    Zieliński A
    Przegl Epidemiol; 1999; 53(3-4):245-55. PubMed ID: 10800562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Herd immunity": a rough guide.
    Fine P; Eames K; Heymann DL
    Clin Infect Dis; 2011 Apr; 52(7):911-6. PubMed ID: 21427399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass vaccination and herd immunity: cattle and buffalo.
    Roeder PL; Taylor WP
    Rev Sci Tech; 2007 Apr; 26(1):253-63. PubMed ID: 17633307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosenescence: Implications for vaccination programmes in adults.
    Lang PO; Govind S; Michel JP; Aspinall R; Mitchell WA
    Maturitas; 2011 Apr; 68(4):322-30. PubMed ID: 21316879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules?
    Lang PO; Aspinall R
    Expert Rev Vaccines; 2012 Feb; 11(2):167-76. PubMed ID: 22309666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.
    Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP
    Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection, reinfection, and vaccination under suboptimal immune protection: epidemiological perspectives.
    Gomes MG; White LJ; Medley GF
    J Theor Biol; 2004 Jun; 228(4):539-49. PubMed ID: 15178201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An unprotected public.
    Kahn J
    Am J Bioeth; 2008 Jun; 8(6):3-4. PubMed ID: 18726767
    [No Abstract]   [Full Text] [Related]  

  • 10. Eradication of infectious diseases: its concept, then and now.
    Arita I; Wickett J; Nakane M
    Jpn J Infect Dis; 2004 Feb; 57(1):1-6. PubMed ID: 14985628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
    Claes C; Reinert RR; von der Schulenburg JM
    Eur J Health Econ; 2009 Feb; 10(1):25-38. PubMed ID: 18379830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vaccination. Basic facts].
    Partouche S; Planquois MC; Rousseau A
    Soins Gynecol Obstet Pueric Pediatr; 1983 Apr; (23):39-46. PubMed ID: 6554924
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation and renewal of vaccination program].
    Melkas T; Hovi T
    Duodecim; 2002; 118(1):55-6. PubMed ID: 12228997
    [No Abstract]   [Full Text] [Related]  

  • 14. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General non-specific morbidity is reduced after vaccination within the third month of life--the Greifswald study.
    Otto S; Mahner B; Kadow I; Beck JF; Wiersbitzky SK; Bruns R
    J Infect; 2000 Sep; 41(2):172-5. PubMed ID: 11023764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination and herd immunity to infectious diseases.
    Anderson RM; May RM
    Nature; 1985 Nov 28-Dec 4; 318(6044):323-9. PubMed ID: 3906406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunoreactivity of individuals in heterogenous populations and immunoprophylaxis of infectious diseases].
    Sokhin AA
    Vestn Akad Med Nauk SSSR; 1983; (5):60-4. PubMed ID: 6868806
    [No Abstract]   [Full Text] [Related]  

  • 19. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.
    Chien YC; Jan CF; Kuo HS; Chen CJ
    Epidemiol Rev; 2006; 28():126-35. PubMed ID: 16782778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Achievements and challenges of the expanded immunization program in the Americas].
    Valenzuela MT; O'Ryan M
    Rev Med Chil; 2000 Aug; 128(8):911-22. PubMed ID: 11129554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.